Clinical trial
Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of…
NCT00218465 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00218465 |
|---|---|
| Title | Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking |
| Official title | A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | National Institute on Drug Abuse (NIDA) NIH Mclean Hospital GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Nicotine Dependence |
| Intervention type | Drug |
| Interventions | GW468816, Placebo Comparator: Placebo |
| Enrollment | 264 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Sep 22, 2005 |
| Last update posted | Mar 24, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: